In Brief: Diolase
This article was originally published in The Gray Sheet
Diolase: Submits corrective action plan and variance request in response to May 23 FDA warning letter for the Diolase Model 100 Therapeutic Laser. The laser, used in the relief of head, neck, jaw and upper back pain, was cited for several issues including labeling, its lack of a remote interlock connector, lack of a "adequate emission delay" and lack of procedures and schedule for recalibration of the system. Diolase's variance request for the device's inadequate emission delay explains that the laser incorporates the ShortStop proximity sensor, which serves to prevent accidental laser beam emission...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.